The running archive.

How a Mazatec healer in Huautla de Jiménez and a New York banker became central, unequal figures in the story of how psilocybin entered Western public awareness.

How Richard Alpert became Ram Dass, why Be Here Now mattered, and how his path diverged from Timothy Leary's while still sharing psychedelic roots.

How Albert Hofmann's Sandoz compound moved from laboratory chemistry into psychiatry, Cold War intelligence programs, and the American counterculture.

The paper behind the headline did find DMT and harmine in a 1,000-year-old ritual bundle from southwestern Bolivia. It did not prove a prepared ayahuasca brew. What it does show is broader and more defensible: multiple psychoactive plants, long-distance movement, and sophisticated botanical knowledge in the pre-Columbian Andes.

The best-supported answer still begins at 5-HT2A, but the downstream story on plasticity and biomarkers is much less settled.

First full week roundup.

Compass says FDA accepted its PTSD IND, while RAND finds 23% of Americans support legal psilocybin mushrooms.

UNM's new Phase 1 PTSD study asks whether psilocybin-assisted therapy can be delivered safely in a peer-supported group format.

Oregon's regulated psilocybin program is real and growing, while Washington's SB 5921 remains stuck in committee.

A Senate bill would establish a VA office for novel therapeutics. A large microdosing diary study found stronger same-day effects than durable carryover. GH001's FDA hold is over, and ibogaine's mechanism looks even stranger up close.

Otsuka is buying Transcend for up to $1.225 billion around a methylone PTSD program that has already reached Phase 3.

The journal said authors withheld protocol violations at the MP4 study site and failed to fully declare competing interests.

Someone asked. So here we are.

Indiana University has posted a not-yet-recruiting psilocybin protocol for veterans and first responders with treatment-resistant depression and co-occurring substance use disorder. Johns Hopkins' OCD study is active but no longer recruiting. UC Irvine is recruiting an ibogaine neuroimaging study in opioid use disorder.

Cybin's CYB003 program is recruiting in phase 3, Mount Sinai is running an MDMA therapist-training study, Brigham has a severe alcohol use disorder protocol queued up, and smaller psilocybin studies in OCD and antidepressant interaction remain active.

After the FDA rejected Lykos' MDMA therapy application, MAPS shifted toward policy, education, and the long game.